The frequency of adverse drug reactions in a tertiary care hostpital in Korea.
- Author:
Jeong Hee CHOI
1
;
Yoo Seob SHIN
;
Chang Hee SUH
;
Dong Ho NAHM
;
Hae Sim PARK
Author Information
1. Department of Allergy and Rheumatology, Ajou University School of Medicine, Suwon, Korea. hspark@ajou.ac.kr
- Publication Type:Original Article
- Keywords:
Adverse drug reaction;
Frequency;
Urticaria and angioedema;
NSAID
- MeSH:
Anaphylaxis;
Angioedema;
Anti-Inflammatory Agents, Non-Steroidal;
beta-Lactams;
Drug-Related Side Effects and Adverse Reactions*;
Epidemiologic Studies;
Exanthema;
Humans;
Incidence;
Korea*;
Prevalence;
Tertiary Healthcare*;
Urticaria
- From:Korean Journal of Medicine
2004;67(3):290-296
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND: The clinical features of adverse drug reactions are various and the incidence is increasing. However, there has been no published data on the prevalence of adverse reactions to drug in Korea. METHODS: There were 301 adverse drug reactions occurring in 287 patients in Ajou University Hospital from May, 2002 through November, 2003. We analyzed the frequency of each causative drugs and clinical manifestations of adverse drug reactions. RESULTS: The most prevalent causative drug was nonsteroidal anti-inflammatory drugs (NSAIDs) (66.5%), followed by antimicrobials (17.8%), anticonvulsant (3.6%) and anti-cancer drug/immunosuppressant (3.3%). The leading clinical feature was cutaneous manifestations (83.1%), especially urticaria/angioedema, followed by respiratory manifestations (16.3%) and anaphylaxis (4.3%). The most common clinical manifestation of adverse drug reactions to NSAIDs was urticaria and/or angioedema (73.8%). Beta-lactams were the most common antimicrobials causing adverse drug reactions, and maculopapular exanthema (53.1%) was the most frequent manifestation. CONCLUSION: The most common causative drug of adverse drug reactions was NSAIDs and the leading clinical feature was cutaneous manifestations in this hospital. Further epidemiologic studies will be needed to extend the overall incidence of adverse drug reactions in this country.
